| Misoprostol for NASH (NCT05804305) | Ziauddin University | 2022-07-01 |
| The Visceral Adiposity Measurement and Observation Study (NCT05383456) | Theratechnologies | 2022-04-18 |
| A Phase II Clinical Trial of Chiglitazar for NASH (NCT05193916) | Chipscreen Biosciences, Ltd. | 2022-03-21 |
| Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 (NCT05203237) | Viking Therapeutics, Inc. | 2021-12-14 |
| Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis (NCT06308757) | University of Bologna | 2021-09-29 |
| Effects of Online App Weight Loss Programs on Liver Health in Obese Adults (NCT05015491) | Noom Inc. | 2021-08-09 |
| Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus (NCT04232293) | Nantes University Hospital | 2021-06-25 |
| THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis) (NCT04925362) | Assistance Publique - Hôpitaux de Paris | 2021-06-01 |
| Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH (NCT04702490) | Metacrine, Inc. | 2020-12-15 |
| A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) (NCT04565717) | Alnylam Pharmaceuticals | 2020-10-09 |
| Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease (NCT06176079) | Michael Ohliger, MD PhD | 2020-07-22 |
| An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol (NCT05874336) | Galmed Pharmaceuticals Ltd | 2020-06-17 |
| LITMUS Imaging Study (NCT05479721) | University of Oxford | 2019-09-04 |
| Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy (NCT03980912) | Fibronostics USA, Inc | 2019-09-01 |
| A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH (NCT04048135) | 89bio, Inc. | 2019-07-29 |
| A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH (NCT04006145) | Albireo | 2019-06-06 |
| DIAbetes and NAFLD (NCT06315361) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2019-05-20 |
| Evaluation of Risk of hEpatocellular Carcinoma (NCT06523179) | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 2018-01-01 |
| A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers (NCT03207425) | Enanta Pharmaceuticals, Inc | 2017-06-14 |
| Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers. (NCT03187496) | Enanta Pharmaceuticals, Inc | 2017-05-11 |
| Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) (NCT02923154) | Tanabe Pharma Corporation | 2016-09-01 |
| The European NAFLD Registry (NCT04442334) | Newcastle University | 2015-05-01 |
| Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease (NCT01269320) | Hadassah Medical Organization | 2012-01-01 |